Skip to main content
Clinical Trials/NCT05141292
NCT05141292
Recruiting
Not Applicable

A Registry Study of Biomarkers in Mitral Valve Disease

Beijing Institute of Heart, Lung and Blood Vessel Diseases1 site in 1 country5,000 target enrollmentApril 1, 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cardiovascular Diseases
Sponsor
Beijing Institute of Heart, Lung and Blood Vessel Diseases
Enrollment
5000
Locations
1
Primary Endpoint
Number of death (all cause)
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

The registry study aims to discover the prognostic value of bio-markers in mitral valve disease

Detailed Description

The purpose of this study is to investigate the prognostic value of biomarkers in mitral valve disease.Patients with confirmed diagnosis of mitral valve disease are enrolled.The primary outcome is all-cause mortality based on the death certificates. The secondary outcome is readmission for heart failure and all-cause mortality/readmission for heart failure according to the patients' medical records.

Registry
clinicaltrials.gov
Start Date
April 1, 2016
End Date
December 31, 2025
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Beijing Institute of Heart, Lung and Blood Vessel Diseases
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients clinically diagnosed with mitral valve disease in Beijing Anzhen Hospital from April 2016 to December 2019
  • The operator performs more than 25 mitral valve operations per year / the operator unit has surgeons who complete 50 operations per year

Exclusion Criteria

  • Age ≤ 18 years
  • Failure to obtain medical records and ultrasound data
  • Refuse follow-up

Outcomes

Primary Outcomes

Number of death (all cause)

Time Frame: 1 years of follow-up

Number of death within 2 years of discharge

Secondary Outcomes

  • Number of rehospitalizations(1 years of follow-up)

Study Sites (1)

Loading locations...

Similar Trials